# A Study to Investigate the Difference In Blood Levels of Camlipixant Between Different Camlipixant Formulation Prototypes

> **NCT07684586** · PHASE1 · WITHDRAWN · sponsor: **GlaxoSmithKline**

## Conditions studied

- Cough

## Interventions

- **DRUG:** Camlipixant

## Key facts

- **NCT ID:** NCT07684586
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2026-07-02
- **Primary completion:** 2027-08-27
- **Final completion:** 2027-08-27
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study has been withdrawn given the recent decision to cease further development of camlipixant in refractory chronic cough (RCC) based on Phase 3 program results.
- **Last updated:** 2026-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07684586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07684586, "A Study to Investigate the Difference In Blood Levels of Camlipixant Between Different Camlipixant Formulation Prototypes". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07684586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*